Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second ...

TeamLease EdTech collaborates with Ministry of Labour & Employment to enhance employability through 200 work-linked degree programs on the National Career Service portal.

Subscribe here to receive future editions. AstraZeneca said it is doubling down on its investment in its U.S. business, a ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

Get the latest bullion rates for gold and silver in India. Check the closing prices for standard gold, ornament gold, and ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...